Search

Background In patients with symptomatic mitral regurgitation who are high risk for surgery, transcatheter mitral-valve repair has been shown to be safe and improve clinical outcomes. However, its impact on survival has shown conflicting results in recent trials. Methods PubMed, EMBASE and Google Scholar databases were queried for all trials about MitraClip compared with optimal medical therapy Results This meta-analysis of 9 trials including 3199 patients, found that patients treated with MitraClip compared to optimal medical therapy had similar 30-day mortality (OR 0.64, 95% CI 0.32- 1.28) while at 12-months MitraClip was associated with significantly lower all-cause mortality (OR 0.46, 95% CI 0.33- 0.65). Absolute risk reduction was 13.9% and number needed to treat to save 1 life at 12 months was 7.2. Figure 1 Conclusions In this meta-analysis, transcatheter mitral valve repair with MitraClip was associated with significantly lower mortality at 12 months of follow up

Renal denervation (RDN) is a catheter-based ablation procedure designed to treat resistant hypertension (RH). The objective of our study is to determine the effect of RDN on blood pressure and renal function in patients with RH in comparison to medical therapy alone. We performed an extensive literature search for randomized control trials (RCT) reporting office and 24 hr. blood pressure changes and estimated glomerular filtration rate (eGFR) at baseline and 6 months. We calculated a weighted standardized mean difference of blood pressure and renal outcomes between RDN and control groups using random effects models. Our search yielded 608 studies of which we included 15 studies for the final analysis. A total of 857 patients were treated with RDN and 616 patients treated with medical therapy ± sham procedure. Only 5 studies were double-blinded RCT with sham control. The adjusted standardized mean difference in the change in office based systolic and diastolic pressures (p = 0.18; p = 0.14); 24 hr. systolic and diastolic pressures (p = 0.20; p = 0.18); and eGFR (p = 0.20) from baseline to 6 months is statistically insignificant with significant heterogeneity. Subgroup analysis showed that among sham controlled trials, 24 hr. systolic blood pressure showed a modest but statistically significant benefit favoring renal denervation in patients with RH. Our meta-analysis of 15 RCTs showed no significant benefit of RDN on blood pressure control in patients with resistant hypertension. Subgroup analysis of sham control studies showed a modest benefit in 24 hr. systolic blood pressure at 6 months with RDN.

Long term outcomes of biodegradable polymer drug-eluting stents (BP-DES) compared to durable polymer drug-eluting stents (DP-DES), are not well described. A comprehensive search in clinicalTrials.gov, PubMed, EBSCO, Web of Science, google scholar and Ovid was performed for RCTs comparing BP-DES and

In patients with symptomatic mitral regurgitation who are high-risk for surgery, transcatheter mitral valve repair has been shown to be safe and improve clinical outcomes. However, its impact on survival has shown conflicting results in recent trials. PubMed, EMBASE, and Google Scholar databases

Long-term freedom from recurrent mitral regurgitation in patients undergoing MitraClip compared to traditional mitral-valve surgery is not known. PubMed, EMBASE, and Google Scholar databases were queried for all trials about MitraClip compared with optimal medical therapy. Seven trials including

Percutaneous mitral valve repair with MitraClip is a promising alternative to traditional mitral valve surgery in patients with severe, symptomatic mitral regurgitation. Impact of MitraClip on survival compared to mitral valve surgery is not known. PubMed, EMBASE, and Google Scholar databases were